Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement…
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…
Six months after its unveiling, the IRO platform is now being deployed to customersLONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) --…
QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael…
WOBURN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cytrellis Biosystems, Inc., a pioneer in novel medical aesthetic solutions, today announced…
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a…
* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%,…
• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation• Recently reported Phase 1…
PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace…
MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today…